A detailed history of Aqr Capital Management LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 26,251 shares of ITOS stock, worth $216,045. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,251
Previous 29,298 10.4%
Holding current value
$216,045
Previous $434,000 38.25%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.09 - $17.97 $30,744 - $54,754
-3,047 Reduced 10.4%
26,251 $268,000
Q2 2024

Aug 14, 2024

SELL
$10.33 - $18.09 $587,467 - $1.03 Million
-56,870 Reduced 66.0%
29,298 $434,000
Q1 2024

May 15, 2024

SELL
$9.89 - $13.64 $77,458 - $106,828
-7,832 Reduced 8.33%
86,168 $1.18 Million
Q4 2023

Feb 14, 2024

BUY
$8.57 - $11.06 $296,693 - $382,897
34,620 Added 58.3%
94,000 $1.03 Million
Q3 2023

Nov 14, 2023

BUY
$10.95 - $14.6 $37,076 - $49,435
3,386 Added 6.05%
59,380 $650,000
Q2 2023

Aug 14, 2023

SELL
$12.93 - $18.05 $1.56 Million - $2.18 Million
-120,828 Reduced 68.33%
55,994 $741,000
Q1 2023

May 15, 2023

SELL
$13.02 - $22.62 $332,283 - $577,285
-25,521 Reduced 12.61%
176,822 $2.41 Million
Q4 2022

Feb 14, 2023

SELL
$17.77 - $21.6 $2.82 Million - $3.42 Million
-158,538 Reduced 43.93%
202,343 $3.95 Million
Q3 2022

Nov 14, 2022

SELL
$18.6 - $27.25 $1.57 Million - $2.3 Million
-84,229 Reduced 18.92%
360,881 $6.88 Million
Q2 2022

Aug 15, 2022

BUY
$16.57 - $35.1 $5.42 Million - $11.5 Million
327,025 Added 276.94%
445,110 $9.17 Million
Q1 2022

May 16, 2022

BUY
$31.92 - $47.45 $3.77 Million - $5.6 Million
118,085 New
118,085 $3.8 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $293M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.